Covering nearly 500 domestic feline tumor samples sourced from five different countries, this study entailed extensive DNA sequencing performed on tissues originally collected for diagnostic purposes by veterinarians. The collaborative effort drew on expertise spanning the Wellcome Sanger Institute, the University of Guelph, the University of Bern, and other leading institutions, heralding a new era of transdisciplinary cancer research. By meticulously analyzing mutational signatures and identifying key cancer-driving genes, the team uncovered striking parallels between the oncogenomes of cats and humans, reaffirming the evolutionary conservation of tumorigenic mechanisms.

Among the pivotal findings is the recurrent mutation in the FBXW7 gene within over half of the feline mammary tumor samples. FBXW7 encodes a crucial component of the ubiquitin-proteasome system, responsible for targeting oncogenic proteins for degradation, and its disruption is well-documented in human breast malignancies as correlating with poor prognosis. The discovery that a similar mutational event occurs prevalently in cats not only reinforces shared molecular pathways but also implicates FBXW7 as a critical oncogenic driver across species.

Further analysis revealed a constellation of driver mutations consistent across diverse tumor types including hematologic, osseous, pulmonary, cutaneous, gastrointestinal, and central nervous system neoplasms. These results emphasize a conserved oncogenic blueprint underlying multiple cancers despite species differences, underscoring the potential influence of common environmental carcinogens impacting domestic animals and their human companions alike. The overlap in mutational landscapes speaks volumes about the co-evolution of cancer biology in shared habitats.

Of particular translational significance, the research team investigated therapeutic susceptibilities in cat mammary tumors harboring FBXW7 mutations. Remarkably, in ex vivo tissue assays, certain chemotherapeutic agents demonstrated heightened efficacy against mutated tumors. Although these findings are preliminary and require clinical validation, they pave the way for precision oncology approaches in feline patients, setting the stage for novel interspecies therapeutic strategies. This cross-pollination of insights hints at a promising “One Medicine” paradigm, wherein veterinary and human oncology can mutually inform and accelerate drug discovery and patient care innovations.

The concept of ‘One Medicine’ champions integrated research that transcends traditional disciplinary boundaries, facilitating a continuous exchange of knowledge between human and veterinary medicine. This international study exemplifies that ethos, demonstrating how comparative oncology can unravel shared genomic drivers of cancer, identify therapeutic targets, and enable the development of treatment modalities applicable to multiple species. Evidence from feline tumors brings invaluable perspectives that could refine human cancer therapies and vice versa, reinforcing the interconnectedness of mammalian health.

Dr. Geoffrey Wood, a pathobiology professor at the University of Guelph and co-senior author, reflects on the transformative potential of this genetic resource. “Before this, the genetic architecture of feline cancers was a complete mystery. With this dataset, we have opened a black box and now hold the keys to detailed molecular understanding that can directly inform diagnostics, prognostics, and therapeutic design.” His insight illustrates the momentum gained in veterinary oncology by harnessing cutting-edge genomic techniques long established in human medicine.

Complementing Dr. Wood’s emphasis, Dr. Sven Rottenberg from the University of Bern highlights the novelty of the drug response data: “Access to a vast repository of donated tissues enabled us to perform unprecedented assessments of chemotherapy efficacy against genetically defined tumor subtypes. This high-resolution pharmacogenomic profiling was simply not feasible before and represents a significant leap for translational research in cats.”

The data also have profound implications for accelerating the detection and management of aggressive malignancies in domestic cats, which remain a leading cause of mortality among pets. By elucidating the molecular drivers of these cancers, veterinarians may soon leverage precision diagnostic tests to stratify patients according to risk and predict therapeutic responses with greater accuracy, improving clinical outcomes and quality of life for feline patients.

Moreover, these insights echo far beyond feline health, as domestic cats frequently share environments with their owners, encountering similar carcinogenic exposures. Identifying shared mutagenic agents and understanding their mechanistic roles across species has the potential to refine public health interventions aimed at mitigating cancer risk in humans and animals alike.

The study further opens the door to innovative clinical trial designs that incorporate domestic cats as biomedical models. Given their spontaneous tumor development and diverse genetic backgrounds, cats may serve as invaluable intermediaries between rodent models and human trials, enhancing predictive validity and facilitating safer, more effective anti-cancer therapeutics.

Looking ahead, the authors envision an exciting future where the integration of oncogenomic data with clinical veterinary practice ushers in an era of precision feline oncology, parallel to advances realized in canine cancer treatment. This will necessitate continued investment in genomic infrastructure, inter-institutional collaborations, and the expansion of biobanking initiatives to capture the heterogeneity of feline cancers worldwide.

This transformative body of work, partly funded by EveryCat Health Foundation, CVS Group, Wellcome, the Natural Sciences and Engineering Research Council of Canada, and the Swiss National Science Foundation, represents a milestone in both veterinary and comparative oncology. By unveiling the oncogenome of the domestic cat, it equips the scientific community with a robust foundation to confront cancer with unified resolve across species boundaries.

Subject of Research: Animal tissue samples
Article Title: The oncogenome of the domestic cat
News Publication Date: 19-Feb-2026
Web References: http://dx.doi.org/10.1126/science.ady6651
Image Credits: University of Guelph
Keywords: feline cancer, oncogenome, FBXW7 mutation, comparative oncology, precision medicine, veterinary pathology, domestic cat tumors, cancer genetics, chemotherapeutic efficacy, One Medicine approach

Analyzing tumor samples from nearly 500 pet cats spanning five countries, the researchers scrutinized the genomic landscapes across 13 distinct cancer types. Employing next-generation sequencing techniques focused on approximately one thousand human cancer-associated genes, the study meticulously compared somatic mutations within feline cancers to those well-characterized in human and canine counterparts, revealing striking overlaps in oncogenic pathways and mutation profiles. This approach not only enhances our understanding of tumorigenesis in cats but also underscores evolutionary conserved mechanisms driving malignancy across species.

Environmental exposures shared between domestic cats and their human cohabitants, such as carcinogenic pollutants and lifestyle factors, provide a compelling context for cross-species cancer risk assessment. Cats’ close proximity to humans affords a unique natural model to investigate environmental etiologies of cancer, and this study leverages that dynamic by analyzing archived diagnostic tissue samples collected by veterinary clinicians. Through integrative bioinformatics analysis, the team identified genetic aberrations in feline cancers that mirror key drivers in human malignancies, suggesting potential commonalities in both etiology and therapeutic vulnerabilities.

One of the most prominent findings centers on feline mammary carcinoma, an aggressive and prevalent cancer subtype in cats analogous to human breast cancer. The study identified seven primary driver genes mutated in the development of these tumors, notably highlighting the FBXW7 gene. Mutations in FBXW7 were found in over half of the feline mammary tumor samples, a figure that resonates with clinical studies in humans where FBXW7 alterations correlate with poor prognosis and treatment resistance. This genetic convergence suggests that feline mammary carcinoma could serve as a pertinent model for studying complex genomic interactions influencing breast cancer progression in humans.

Further functional assays using cultured feline mammary carcinoma tissues revealed that tumors harboring FBXW7 mutations exhibited differential responses to specific chemotherapeutic agents. Although preliminary and conducted ex vivo, these findings pave the way for future translational research to explore targeted therapies that could benefit both feline and human patients. Such insights exemplify the promise of precision medicine approaches tailored to genetic subtypes across species.

Closely following FBXW7 in mutational frequency was PIK3CA, mutated in nearly half of the feline mammary carcinoma cases. This gene encodes a catalytic subunit of phosphatidylinositol 3-kinase (PI3K), a critical component in cell growth and survival signaling pathways frequently dysregulated in human breast cancer. The demonstrated presence of PIK3CA mutations in cats emanates exciting possibilities for testing PI3K inhibitors, drugs already approved for humans, within veterinary oncology settings, catalyzing bidirectional advancements in cancer therapeutics.

Beyond mammary carcinomas, the genomic landscape elucidated in this study extends to other malignant neoplasms such as hematologic, osteogenic, pulmonary, cutaneous, gastrointestinal, and central nervous system tumors. The identification of shared mutational signatures and oncogenic drivers across these diverse cancer types supports the concept of conserved oncogenic processes and opens the door to cross-species therapeutic explorations. Researchers posit that emerging treatments effective in human oncology could be judiciously adapted for feline patients, while feline clinical trials might reciprocally inform human cancer drug development.

This visionary “One Medicine” framework embodies a truly integrative approach, promoting synergy between veterinary and human medical disciplines. Facilitated by open data sharing and collaborative research consortia, this paradigm nurtures a two-way data exchange that accelerates understanding of tumor biology, improves animal health, and guides innovative human clinical interventions. The massive dataset generated by this study serves as a pioneering genomic resource, freely accessible to the scientific community for ongoing feline cancer research.

From a public health perspective, these findings bear particular significance given that domestic cats inhabit nearly a quarter of UK households, with over ten million feline companions nationwide. As cancer remains a leading cause of morbidity and mortality in cats, elucidating the genetic underpinnings of their cancers addresses a vital veterinary need, improves diagnostic precision, and lays the groundwork for targeted therapies previously unavailable within this population.

Lead co-author Bailey Francis emphasizes that comparative genomics involving cats, dogs, and humans enriches our grasp of cancer causality and progression. Collaborative, multispecies research efforts harness comparative oncogenomics to overcome limitations intrinsic to individual species studies, ultimately propelling advancements in cancer biology that transcend species boundaries.

Professor Geoffrey Wood from the Ontario Veterinary College highlights that although domestic cats are frequent domestic animals, their cancer genomics have been understudied until now. The innate exposure of cats to shared environmental carcinogens with humans positions them as valuable sentinels for investigating cancer risk factors, mechanisms, and prevention strategies applicable to both human and veterinary medicine.

Professor Sven Rottenberg of the University of Bern remarks on the unprecedented scale of drug response profiling enabled by access to a vast collection of donated feline tumor tissues. This resource allows functional assessments that were previously impractical and holds the promise of identifying novel therapeutic compounds with cross-species efficacy, potentially revolutionizing oncology practice.

Senior author Dr. Louise Van Der Weyden from the Wellcome Sanger Institute characterizes this study as a monumental advance in feline oncology, transforming the once opaque genetics of domestic cat cancers into a well-delineated genomic landscape. This breakthrough paves the way for precision oncology in feline medicine and aims to bridge diagnostic and treatment gaps compared to canine and human practices.

Collectively, the insights from this research represent a major stride toward realizing precision medicine approaches in veterinary oncology, leveraging comparative genomics for shared benefit across species. By unlocking the oncogenomic secrets of the domestic cat, scientists now possess critical tools to advance tailored interventions that improve outcomes for feline patients and accelerate cancer treatment innovation in humans.

Subject of Research: Animal tissue samples
Article Title: The oncogenome of the domestic cat
News Publication Date: 19-Feb-2026
References:

• A. L. Sarver, K. M. Makielski, T. A. DePauw, A. J. Schulte, J. F. Modiano. (2022) ‘Increased risk of cancer in dogs and humans: a consequence of recent extension of lifespan beyond evolutionarily-determined limitations?’ Aging Cancer. DOI: 10.1002/aac2.12046
• B. A. Francis, L. Ludwig, C. He, et al. (2026) ‘The oncogenome of the domestic cat’. Science. DOI: 10.1126/science.ady6651
  Image Credits: Victoria Hatch
  Keywords: Cancer genomics, Animal science, Animal health, Veterinary medicine